ALGO Rises 1.64% Amid Stock Option Grants and Market Volatility

Aligos Therapeutics Grants Stock Options to New Hires

On November 11, 2025, Aligos Therapeutics, Inc. (Nasdaq: ALGS) announced the issuance of non-qualified stock options to newly hired employees under its 2024 Inducement Plan. The options cover 23,600 shares of the company’s stock and are structured to incentivize new talent under Nasdaq Listing Rule 5635(c)(4). The exercise price was set at the closing price of Aligos' common stock on the grant date. These options will vest over four years, with 25% vesting on the first anniversary of the grant date and the remaining vesting in equal monthly installments thereafter. This move is part of Aligos’ ongoing strategy to attract and retain talent in its mission-driven biopharmaceutical development.

Market Volatility and Economic Calendar Events

Despite a 1.64% increase in the last 24 hours, ALGO has experienced a 7.46% decline over the past week, a 12.63% drop in a month, and a significant 53.66% decline in the past year. Market participants continue to monitor economic calendar events, with key data expected on November 19, 2025. The United States will see the release of FOMC meeting minutes and crude oil inventory figures, while the United Kingdom and Eurozone will release CPI data. These releases could influence broader market sentiment and investor behavior, particularly as central bank policy remains a focal point for global markets.

Corporate Governance and Strategic Moves

In separate news, Eshallgo Inc. (Nasdaq: EHGO) announced strategic progress in its global expansion, including new partnerships and the formation of a U.S. subsidiary. The company highlighted its investments in integrated hardware-software solutions and compliance initiatives to align with U.S. public company standards. Additionally, Eshallgo filed a shelf registration to provide flexibility in capital access. While these developments are company-specific, they reflect broader industry trends of internationalization and operational strengthening.

Economic Calendar and Market Events

The upcoming economic calendar is set to bring a wave of inflation data and key policy-related announcements, which could influence investor sentiment across asset classes. Traders will closely watch developments in manufacturing, retail sales, and central bank communication. The data will be critical in shaping expectations for monetary policy, especially as market participants assess the likelihood of rate cuts.

Corporate Actions and Shareholder Activities

Corporate actions, such as stock option grants and insider transactions, continue to draw attention. For instance, a vice president at Allogene Therapeutics filed to sell a portion of restricted shares, while a CEO at Alamo Group Inc. increased his stake. These transactions offer insights into insider sentiment and can influence short-term stock price movements.

In conclusion, while ALGO experienced a short-term upward movement in the 24-hour period, the broader trend remains downward. Investors should consider both macroeconomic indicators and company-specific developments when evaluating exposure to ALGO and related assets.